Kendra E Wulczyn1, Sophia H Zhao2, Eugene P Rhee3,4, Sahir Kalim2, Tariq Shafi5,6,7. 1. Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts kwulczyn@partners.org. 2. Department of Medicine, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts. 4. Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts. 5. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi. 6. Department of Population Health, Bower School of Population Health, University of Mississippi Medical Center, Jackson, Mississippi. 7. Department of Physiology and Biophysics, University of Mississippi Medical Center School of Medicine, Jackson, Mississippi.
Abstract
BACKGROUND AND OBJECTIVES: Uremic symptoms, including fatigue, anorexia, pruritus, nausea, paresthesia, and pain, are attributed to the accumulation of organic waste products normally cleared by the kidneys, but whether kidney function is the primary driver of changes in symptom severity over time is not known. The goal of our study was to evaluate the association between eGFR and uremic symptom severity score in patients with CKD. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We identified 3685 participants with CKD not on dialysis in the prospective, observational Chronic Renal Insufficiency Cohort (CRIC) Study with baseline assessment of eGFR and uremic symptom severity. Symptoms were assessed by separate questions on the Kidney Disease Quality of Life-36 instrument (zero- to 100-point scale). The longitudinal association between eGFR and uremic symptom severity score was examined with multivariable adjusted linear mixed-effects models with random intercepts and random slopes. RESULTS: The mean±SD eGFR at baseline was 44±15 ml/min per 1.73 m2, and participants had a median of six (interquartile range 3-11) simultaneous assessments of eGFR and uremic symptoms over the duration of follow-up. The most prevalent symptoms at baseline were pain (57%), fatigue (52%), paresthesia (45%), and pruritus (42%). In adjusted models, a decrease in eGFR of 5 ml/min per 1.73 m2 was associated with a worsening of the symptom severity score by two points or less for each uremic symptom (P<0.01; zero- to 100-point scale). The association between eGFR and uremic symptom severity score was nonlinear. When starting from a lower initial eGFR, a 5 ml/min per 1.73 m2 decrease in eGFR was associated with a greater magnitude of uremic symptom worsening. CONCLUSIONS: The prevalence of uremic symptoms in CKD is high, with significant variability in patient symptom change over time. Declines in eGFR were associated with worsening of uremic symptom severity, but the magnitude of these changes is small and of uncertain clinical significance.
BACKGROUND AND OBJECTIVES: Uremic symptoms, including fatigue, anorexia, pruritus, nausea, paresthesia, and pain, are attributed to the accumulation of organic waste products normally cleared by the kidneys, but whether kidney function is the primary driver of changes in symptom severity over time is not known. The goal of our study was to evaluate the association between eGFR and uremic symptom severity score in patients with CKD. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We identified 3685 participants with CKD not on dialysis in the prospective, observational Chronic Renal Insufficiency Cohort (CRIC) Study with baseline assessment of eGFR and uremic symptom severity. Symptoms were assessed by separate questions on the Kidney Disease Quality of Life-36 instrument (zero- to 100-point scale). The longitudinal association between eGFR and uremic symptom severity score was examined with multivariable adjusted linear mixed-effects models with random intercepts and random slopes. RESULTS: The mean±SD eGFR at baseline was 44±15 ml/min per 1.73 m2, and participants had a median of six (interquartile range 3-11) simultaneous assessments of eGFR and uremic symptoms over the duration of follow-up. The most prevalent symptoms at baseline were pain (57%), fatigue (52%), paresthesia (45%), and pruritus (42%). In adjusted models, a decrease in eGFR of 5 ml/min per 1.73 m2 was associated with a worsening of the symptom severity score by two points or less for each uremic symptom (P<0.01; zero- to 100-point scale). The association between eGFR and uremic symptom severity score was nonlinear. When starting from a lower initial eGFR, a 5 ml/min per 1.73 m2 decrease in eGFR was associated with a greater magnitude of uremic symptom worsening. CONCLUSIONS: The prevalence of uremic symptoms in CKD is high, with significant variability in patient symptom change over time. Declines in eGFR were associated with worsening of uremic symptom severity, but the magnitude of these changes is small and of uncertain clinical significance.
Authors: Moniek W M van de Luijtgaarden; Fergus J Caskey; Christoph Wanner; Nicholas C Chesnaye; Maurizio Postorino; Cynthia J Janmaat; Anirudh Rao; Claudia Torino; Marian Klinger; Christiane Drechsler; Olof Heimburger; Maciej Szymczak; Marie Evans; Friedo W Dekker; Kitty J Jager Journal: Nephrol Dial Transplant Date: 2019-07-01 Impact factor: 5.992
Authors: Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Morgan E Grams; Aditya Surapaneni; Lawrence J Appel; James P Lash; Jesse Hsu; Clarissa J Diamantidis; Sylvia E Rosas; Jeffrey C Fink; Julia J Scialla; James Sondheimer; Chi-Yuan Hsu; Alfred K Cheung; Bernard G Jaar; Sankar Navaneethan; Debbie L Cohen; Sarah Schrauben; Dawei Xie; Pandu Rao; Harold I Feldman Journal: Nephrol Dial Transplant Date: 2021-08-27 Impact factor: 7.186
Authors: Stephanie A Brown; Freya C Tyrer; Amy L Clarke; Laetitia H Lloyd-Davies; Andrew G Stein; Carolyn Tarrant; James O Burton; Alice C Smith Journal: Clin Kidney J Date: 2017-07-10